Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Bonetti

Showing results (121-130 of 132) with videos related to

Pageof 14
Sort By:
Systematic and Applied Microbiology|December 6, 2020
Corrigendum to Characterization of Bifidobacterium species in feaces of the Egyptian fruit bat: Description of Bifidobacterium vespertilionis sp. nov. and Bifidobacterium rousetti sp. nov. [Syst. Appl. Microbiol. 42 (2019) 126017]Monica Modesto, Maria Satti, Koichi Watanabe, et al.
Tumori|April 11, 2022
First-line treatment of metastatic castration-resistant prostate cancer: the real-world Italian cohort of the Prostate Cancer RegistryLuca Galli, Vincenzo Emanuele Chiuri, Giuseppe Di Lorenzo, et al.
Breast Cancer Research and Treatment|April 12, 2011
Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective studyManuela Campiglio, Rosaria Bufalino, Marco Sandri, et al.
Plos One|March 16, 2021
Psychological impact of Covid-19 pandemic on oncological patients: A survey in Northern ItalyEva Pigozzi, Daniela Tregnago, Lucia Costa, et al.
The Oncologist|March 9, 2019
From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for <i>EGFR</i>-Positive Non-Small Cell Lung Cancer (MOST Study)Giulia Pasello, Giovanni Vicario, Fable Zustovich, et al.
ESMO Open|July 19, 2018
TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable <i>RAS</i> and <i>BRAF</i> wild-type metastatic colorectal cancerBeatrice Borelli, Roberto Moretto, Sara Lonardi, et al.
European Journal of Cancer (Oxford, England : 1990)|February 16, 2022
Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrantLuca Malorni, Svitlana Tyekucheva, Florentine S Hilbers, et al.
Future Oncology (London, England)|January 19, 2016
Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancerAntonello Veccia, Orazio Caffo, Ugo De Giorgi, et al.
BMC Cancer|March 30, 2019
Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trialMaria Di Bartolomeo, Monica Niger, Federica Morano, et al.
Cancer Discovery|June 29, 2021
Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening InitiativePhilippe Aftimos, Mafalda Oliveira, Alexandre Irrthum, et al.
Pageof 14

Showing results (121-130 of 132) with videos related to

Sort By:
Pageof 14
Systematic and Applied Microbiology|December 6, 2020
Corrigendum to Characterization of Bifidobacterium species in feaces of the Egyptian fruit bat: Description of Bifidobacterium vespertilionis sp. nov. and Bifidobacterium rousetti sp. nov. [Syst. Appl. Microbiol. 42 (2019) 126017]Monica Modesto, Maria Satti, Koichi Watanabe, et al.
Tumori|April 11, 2022
First-line treatment of metastatic castration-resistant prostate cancer: the real-world Italian cohort of the Prostate Cancer RegistryLuca Galli, Vincenzo Emanuele Chiuri, Giuseppe Di Lorenzo, et al.
Breast Cancer Research and Treatment|April 12, 2011
Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective studyManuela Campiglio, Rosaria Bufalino, Marco Sandri, et al.
Plos One|March 16, 2021
Psychological impact of Covid-19 pandemic on oncological patients: A survey in Northern ItalyEva Pigozzi, Daniela Tregnago, Lucia Costa, et al.
The Oncologist|March 9, 2019
From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for <i>EGFR</i>-Positive Non-Small Cell Lung Cancer (MOST Study)Giulia Pasello, Giovanni Vicario, Fable Zustovich, et al.
ESMO Open|July 19, 2018
TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable <i>RAS</i> and <i>BRAF</i> wild-type metastatic colorectal cancerBeatrice Borelli, Roberto Moretto, Sara Lonardi, et al.
European Journal of Cancer (Oxford, England : 1990)|February 16, 2022
Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrantLuca Malorni, Svitlana Tyekucheva, Florentine S Hilbers, et al.
Future Oncology (London, England)|January 19, 2016
Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancerAntonello Veccia, Orazio Caffo, Ugo De Giorgi, et al.
BMC Cancer|March 30, 2019
Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trialMaria Di Bartolomeo, Monica Niger, Federica Morano, et al.
Cancer Discovery|June 29, 2021
Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening InitiativePhilippe Aftimos, Mafalda Oliveira, Alexandre Irrthum, et al.
Pageof 14